These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12671776)

  • 1. Use of bDNA testing in the immunologically nonresponding patient who has a low or undetectable viral load by RT-PCR testing.
    Grimes RM; Lewis ST; Visnegarwala F; Goodly J; Sutton R; Rodriguez-Barradas M
    HIV Clin Trials; 2003; 4(2):92-8. PubMed ID: 12671776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability at the lower limits of HIV-1 RNA quantification in clinical samples: a comparison of RT-PCR versus bDNA assays.
    Lubelchek RJ; Max B; Sandusky CJ; Hota B; Barker DE
    PLoS One; 2009 Jun; 4(6):e6008. PubMed ID: 19547711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical comparison of branched DNA and reverse transcriptase-PCR and nucleic acid sequence-based amplification assay for the quantitation of circulating recombinant form_BC HIV-1 RNA in plasma.
    Pan P; Tao X; Zhang Q; Xing W; Sun X; Pei L; Jiang Y
    AIDS; 2007 Dec; 21 Suppl 8():S27-32. PubMed ID: 18172387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?
    Poveda E; de Mendoza C; Cuesta M; Toro C; Rodés B; Soriano V
    AIDS Patient Care STDS; 2003 Jul; 17(7):321-4. PubMed ID: 12952733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay.
    Sivapalasingam S; Wangechi B; Marshed F; Laverty M; Essajee S; Holzman RS; Valentine F
    PLoS One; 2009 Aug; 4(8):e6828. PubMed ID: 19714253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses.
    Swanson P; Huang S; Abravaya K; de Mendoza C; Soriano V; Devare SG; Hackett J
    J Virol Methods; 2007 Apr; 141(1):49-57. PubMed ID: 17184853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples.
    Berger A; Scherzed L; Stürmer M; Preiser W; Doerr HW; Rabenau HF
    J Clin Virol; 2005 May; 33(1):43-51. PubMed ID: 15797364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV reverse transcriptase activity assay: a feasible surrogate for HIV viral load measurement in China.
    Huang D; Zhuang Y; Zhai S; Song Y; Liu Q; Zhao S; Wang S; Li X; Kang W; Greengrass V; Plate M; Crowe SM; Sun Y
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):208-13. PubMed ID: 20846816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular-based methods for quantifying HIV viral load.
    Peter JB; Sevall JS
    AIDS Patient Care STDS; 2004 Feb; 18(2):75-9. PubMed ID: 15006182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens.
    Galli R; Merrick L; Friesenhahn M; Ziermann R
    J Clin Virol; 2005 Dec; 34(4):245-52. PubMed ID: 16286047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
    Newman H; Breunig L; van Zyl G; Stich A; Preiser W
    J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.
    Kieffer TL; Finucane MM; Nettles RE; Quinn TC; Broman KW; Ray SC; Persaud D; Siliciano RF
    J Infect Dis; 2004 Apr; 189(8):1452-65. PubMed ID: 15073683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.